Different Clinicopathologic and Computed Tomography Imaging Characteristics of Primary and Acquired EGFR T790M Mutations in Patients with Non-Small-Cell Lung Cancer

References

• SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• SankarK, GadgeelSM, QinA. Molecular therapeutic targets in non-small cell lung cancer. Expert Rev Anticancer Ther. 2020;20:647–661. doi:10.1080/14737140.2020.178715632580596
   PubMed Web of Science ®Google Scholar
• CastellanosE, FeldE, HornL. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 2017;12:612–623. doi:10.1016/j.jtho.2016.12.01428017789
   PubMed Web of Science ®Google Scholar
• DeardenS, StevensJ, WuYL, BlowersD. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;2:2371–2376. doi:10.1093/annonc/mdt205
   Web of Science ®Google Scholar
• LynchTJ, BellDW, SordellaR, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139. doi:10.1056/NEJMoa04093815118073
   PubMed Web of Science ®Google Scholar
• GazdarAF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28:S24–S31. doi:10.1038/onc.2009.19819680293
   PubMed Web of Science ®Google Scholar
• CataldoVD, GibbonsDL, Pérez-SolerR, Quintás-CardamaA. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011;364:947–955. doi:10.1056/NEJMct080796021388312
   PubMed Web of Science ®Google Scholar
• ShiYK, WangL, HanBH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a Phase 3, open-label, randomized study. Ann Oncol. 2017;28:2443–2450. doi:10.1093/annonc/mdx35928945850
   PubMed Web of Science ®Google Scholar
• YangJC, WuYL, SchulerM, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomized, phase 3 trials. Lancet Oncol. 2015;16:141–151. doi:10.1016/S1470-2045(14)71173-825589191
   PubMed Web of Science ®Google Scholar
• LimSM, SynNL, ChoBC, SooRA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1–10. doi:10.1016/j.ctrv.2018.02.00629477930
   PubMed Web of Science ®Google Scholar
• YuHA, ArcilaME, RekhtmanN, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR‐mutant lung cancers. Clin Cancer Res. 2013;19:2240–2247. doi:10.1158/1078-0432.CCR-12-224623470965
   PubMed Web of Science ®Google Scholar
• ChenLY, Molina-VilaMA, RuanSY, et al. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2016;94:46–53. doi:10.1016/j.lungcan.2016.01.01926973206
   PubMed Web of Science ®Google Scholar
• YuHA, ArcilaME, HellmannMD, KrisMG, LadanyiM, RielyGJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol. 2014;5:423–428. doi:10.1093/annonc/mdt573
   Web of Science ®Google Scholar
• RosellR, MolinaMA, CostaC, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011;17:1160–1168. doi:10.1158/1078-0432.CCR-10-215821233402
   PubMed Web of Science ®Google Scholar
• SuKY, ChenHY, LiKC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30:433–440. doi:10.1200/JCO.2011.38.322422215752
   PubMed Web of Science ®Google Scholar
• JännePA, YangJC, KimDW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689–1699. doi:10.1056/NEJMoa141181725923549
   PubMed Web of Science ®Google Scholar
• WangS, YanB, ZhangY, et al. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. Int J Cancer. 2019;144:2880–2886. doi:10.1002/ijc.3201530474188
   PubMed Web of Science ®Google Scholar
• LiW, QiuT, GuoL, et al. Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Cancer Lett. 2018;423:9–15. doi:10.1016/j.canlet.2018.03.00529524556
   PubMed Web of Science ®Google Scholar
• HochmairMJ, MorabitoA, HaoD. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncol. 2020;16:2799–2808. doi:10.2217/fon-2020-074032854536
   PubMed Web of Science ®Google Scholar
• ShahR, LesterJF. Tyrosine kinase inhibitors for the treatment of EGFR Mutation-positive non-small-cell lung cancer: a clash of the generations. Clin Lung Cancer. 2020;21:e216–e228. doi:10.1016/j.cllc.2019.12.00332014348
   PubMed Web of Science ®Google Scholar
• PlanchardD, PopatS, KerrK, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–iv237. doi:10.1093/annonc/mdy275
   PubMed Web of Science ®Google Scholar
• LambinP, Rios-VelazquezE, LeijenaarR, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–446. doi:10.1016/j.ejca.2011.11.03622257792
   PubMed Web of Science ®Google Scholar
• TravisWD, BrambillaE, NoguchiM, et al. International association for the study of lung cancer/american thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–285. doi:10.1097/JTO.0b013e318206a22121252716
   PubMed Web of Science ®Google Scholar
• ShanL, WangZ, GuoL, et al. Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Lung Cancer. 2015;89:337–342. doi:10.1016/j.lungcan.2015.06.00826141217
   PubMed Web of Science ®Google Scholar
• LiuY, KimJ, QuF, et al. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiology. 2016;280:271–280. doi:10.1148/radiol.201615145526937803
   PubMed Web of Science ®Google Scholar
• ZwirewichCV, VedalS, MillerRR, MüllerNL. Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation. Radiology. 1991;179:469–476. doi:10.1148/radiology.179.2.20142942014294
   PubMed Web of Science ®Google Scholar
• ZhouLN, WuN, ZhaoSJ, et al. HRCT features differentiate synchronous multiple primary lung adenocarcinomas from intrapulmonary metastases. Zhonghua Zhong Liu Za Zhi. 2020;42:449–455. doi:10.3760/cma.j.cn112152-20200227-0012632575939
   PubMedGoogle Scholar
• ZhangY, LiG, LiY, et al. Imaging features suggestive of multiple primary lung adenocarcinomas. Ann Surg Oncol. 2020;27:2061–2070. doi:10.1245/s10434-019-08109-w31863415
   PubMed Web of Science ®Google Scholar
• DingC, PengH. Minimum redundancy feature selection from microarray gene expression data. J Bioinform Comput Biol. 2005;3:185–205. doi:10.1142/S021972000500100415852500
   PubMedGoogle Scholar
• TibshiraniR. Regression shrinkage and selection via the lasso: a retrospective. J R Stat Soc Series B Stat Methodol. 2011;73:273–282. doi:10.1111/j.1467-9868.2011.00771.x
   Web of Science ®Google Scholar
• KramerAA, ZimmermanJE. Assessing the calibration of mortality benchmarks in critical care: the Hosmer-Lemeshow test revisited. Crit Care Med. 2007;35:2052–2056. doi:10.1097/01.CCM.0000275267.64078.B017568333
   PubMed Web of Science ®Google Scholar
• ArrietaO, CardonaAF, CorralesL, et al. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer. 2015;87:169–175. doi:10.1016/j.lungcan.2014.12.00925558790
   PubMed Web of Science ®Google Scholar
• FujitaY, SudaK, KimuraH, et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol. 2012;7:1640–1644. doi:10.1097/JTO.0b013e3182653d7f22899358
   PubMed Web of Science ®Google Scholar
• LavdovskaiaED, IyevlevaAG, SokolenkoAP, et al. EGFR T790M mutation in TKI-naïve clinical samples: frequency, tissue mosaicism, predictive value and awareness on artifacts. Oncol Res Treat. 2018;41:634–642. doi:10.1159/00049144130145586
   PubMed Web of Science ®Google Scholar
• IwamaE, TakayamaK, HaradaT, et al. Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. Oncotarget. 2015;6:20466–20473. doi:10.18632/oncotarget.405826015401
   PubMedGoogle Scholar
• YeX, ZhuZZ, ZhongL, et al. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?J Thorac Oncol. 2013;8:1118–1120. doi:10.1097/JTO.0b013e31829f691f23945382
   PubMed Web of Science ®Google Scholar
• ChmieleckiJ, FooJ, OxnardGR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3:90ra59. doi:10.1126/scitranslmed.3002356
   PubMed Web of Science ®Google Scholar
• KawamuraT, KenmotsuH, OmoriS, et al. Clinical factors predicting detection of T790M mutation in rebiopsy for EGFR-mutant non-small-cell lung cancer. Clin Lung Cancer. 2018;19:e247–e252. doi:10.1016/j.cllc.2017.07.00228866043
   PubMed Web of Science ®Google Scholar
• HashidaS, SohJ, ToyookaS, et al. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients. Oncol Rep. 2014;32:145–152. doi:10.3892/or.2014.319724842519
   PubMed Web of Science ®Google Scholar
• SakashitaS, Shiba-IshiiA, MurataY, et al. Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology. Pathol Res Pract. 2018;214:1224–1230. doi:10.1016/j.prp.2018.05.01629887244
   PubMed Web of Science ®Google Scholar
• WangX, LiX, GuoH, et al. Highly sensitive droplet digital PCR method for detection of de novo EGFR T790M mutation in patients with non-small cell lung cancer. Onco Targets Ther. 2020;13:10621–10630. doi:10.2147/OTT.S26767733116639
   PubMed Web of Science ®Google Scholar
• YotsukuraM, YasudaH, ShigenobuT, et al. Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma. Lung Cancer. 2017;109:45–51. doi:10.1016/j.lungcan.2017.04.01428577949
   PubMed Web of Science ®Google Scholar
• SudaK, MitsudomiT, ShintaniY, et al. Japanese Joint Committee of Lung Cancer Registry. Clinical impacts of EGFR mutation status: analysis of 5780 surgically resected lung cancer cases. Ann Thorac Surg. 2021;111:269–276. doi:10.1016/j.athoracsur.2020.05.04132615091
   PubMed Web of Science ®Google Scholar
• WengCF, ChenPJ, TsengAH, HuangSH, Hsin-ChunH. Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer. World J Surg Oncol. 2019;17:2–6. doi:10.1186/s12957-019-1688-330606203
   PubMed Web of Science ®Google Scholar
• BaiY, QiuJ, ShangX, et al. Differential diagnosis and cancer staging of a unique case with multiple nodules in the lung – lung adenocarcinoma, metastasis of colon adenocarcinoma, and colon adenocarcinoma metastasizing to lung adenocarcinoma. Thorac Cancer. 2015;6:363–367. doi:10.1111/1759-7714.1217326273385
   PubMed Web of Science ®Google Scholar
• SunF, XiJ, ZhanC, et al. Ground glass opacities: imaging, pathology, and gene mutations. J Thorac Cardiovasc Surg. 2018;156:808–813. doi:10.1016/j.jtcvs.2018.02.11029753514
   PubMed Web of Science ®Google Scholar
• YangY, YangY, ZhouX, et al. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. Lung Cancer. 2015;87:272–277. doi:10.1016/j.lungcan.2014.12.01625582278
   PubMed Web of Science ®Google Scholar
• GilliesRJ, KinahanPE, HricakH. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563–577. doi:10.1148/radiol.201515116926579733
   PubMed Web of Science ®Google Scholar
• JiY, QiuQ, FuJ, et al. Stage-specific PET radiomic prediction model for the histological subtype classification of non-small-cell lung cancer. Cancer Manag Res. 2021;13:307–317. doi:10.2147/CMAR.S28712833469373
   PubMed Web of Science ®Google Scholar
• TrebeschiS, DragoSG, BirkbakNJ, et al. Predicting response to cancer immunotherapy using non-invasive radiomic biomarkers. Ann Oncol. 2019;30:998–1004. doi:10.1093/annonc/mdz10830895304
   PubMed Web of Science ®Google Scholar